test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/22761


Title: Vaccines against Neisseria meningitidis: past, present and future
Issue Date: 31-Dec-1996
Publisher: Elfos Scientiae
Citation: Biotecnologia Aplicada (ISSN: 0684-4551) Vol 13 Num 1
Abstract: Biotecnologia Aplicada 1996;13:1-7 Vaccines against Neisseria meningitidis: past, present and future Dlawer A. A. Ala'Aldeen. Recibido en septiembre de 1995. Aprobado en octubre de 1995 Code Number: BA96001 Size of Files: Text: 50.8K No associated graphics files SUMMARY The ultimate goal in meningococcal vaccine research is the development of an ideal vaccine which is safe, offers long lasting immunity to all age groups, cross-protects against all meningococcal serogroups, serotypes and serosubtypes, be given orally or nasally and be easily incorporated into the World Health Organisation's Expanded Program on Immunisation. So far no such vaccine has been developed. Vaccines based on the capsular polysaccharides are available against serogroups A, C, W135 and Y which offer good, but relatively short-lived, protection against their respective serogroups. These vaccines do not cross-protect against serogroup B meningococci. Various alternative approaches have been now explored, including improved capsular polysaccharides and preparations of outer membrane proteins (constitutively expressed or iron-regulated). Over the past few years there has been considerable activity in the field and a number of clinical trials were conducted on various vaccine preparations with varying successes. We may witness research breakthroughs in the foreseeable future, however, it may be some time before a broadly or universally cross-protective vaccine becomes available. Key words: Meningococci, vaccines, iron, iron-regulated proteins, transferrin, transferrin-binding proteins, outer membrane proteins, capsule, polysaccharide, immune response RESUMEN La vacuna antimeningococcica ideal debe ser segura, conferir una inmunidad duradera en todos los grupos etarios, proteger contra todos los serogrupos, serotipos y serosubtipos de Neisseria meningitidis, administrarse oral o nasalmente, y poder ser incorporada con facilidad dentro del Programa Ampliado de Inmunizacion de la Organizacion Mundial de la Salud. Hasta ahora tales objetivos no se han alcanzado. Existen vacunas basadas en el polisacarido capsular contra los serogrupos A, C, W135 y Y, las cuales ofrecen una buena, aunque relativamente corta, proteccion contra sus serogrupos respectivos. estas no ofrecen proteccion cruzada contra el serogrupo B. Para lograrlo se han explorado varios enfoques alternativos, incluyendo polisacaridos capsulares mejorados y preparaciones de proteinas de membrana externa (de expresion constitutiva o reguladas por hierro). Ha habido una considerable actividad en este campo durante los ultimos anos y varias preparaciones vacunales han sido llevadas a pruebas clinicas con diferentes grados de exito. Aunque es posible que presenciemos adelantos cardinales en este campo en el futuro cercano, puede pasar algun tiempo antes de que dispongamos de una vacuna antimeningococcica de amplio espectro de proteccion. Palabras claves: Meningococci, vacunas, hierro, proteinas reguladas por hierro, polisacarido, transferrina, proteinas de membrana externa, proteinas de union de transferrina, capsula, respuesta inmune Copyright 1996 Elfos Scientiae
URI: http://hdl.handle.net/1807/22761
Other Identifiers: http://www.bioline.org.br/abstract?id=ba96001
Rights: Copyright 1996 Elfos Scientiae
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
ba96001.html52.47 kBHTMLView/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft